Eli Lilly's oral Foundayo beats oral semaglutide on weight loss and A1C at 52 weeks in indirect comparison presented at EASD

Eli Lilly's once-daily oral Foundayo 17.2 mg outperformed oral semaglutide 25 mg on weight loss and A1C at 52 weeks in an indirect comparison in type 2 diabetes, presented at EASD in Milan. Lilly said Foundayo topped oral semaglutide in the new diabetes analysis.

Detected & updated continuously · Source: Nebula